We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+8.34%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.86B
AUM Growth
+$107M
Cap. Flow
+$60.9M
Cap. Flow %
2.13%
Top 10 Hldgs %
78.63%
Holding
49
New
5
Increased
3
Reduced
–
Closed
5

Top Buys

Rank Stock Value
1
SYBX
Synlogic
SYBX
+$46.3M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$35M
3
IMMU
Immunomedics Inc
IMMU
+$27.6M
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$15.4M
5
RGLS
Regulus Therapeutics
RGLS
+$11.5M

Top Sells

Rank Stock Value
1
GRPN icon
Groupon
GRPN
+$38.5M
2
NVRO
NEVRO CORP.
NVRO
+$26.8M
3
SNAP icon
Snap
SNAP
+$14.5M
4
HIVE
Aerohive Networks
HIVE
+$5.61M
5
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$1.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.61%
2 Consumer Discretionary 1.81%
3 Technology 0.87%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$1.33B 46.46%
10,275,113
– –
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$141M 4.93%
325,771
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$123M 4.31%
6,460,851
+200,000
+3% +$3.05M
CBIO
4
Crescent Biopharma
CBIO
$598M
$120M 4.21%
85,841
– –
SENS icon
5
Senseonics Holdings Inc
SENS
$255M
$107M 3.73%
1,671,264
– –
ADAP
6
DELISTED
Adaptimmune Therapeutics
ADAP
$98.5M 3.45%
12,025,999
– –
DERM
7
DELISTED
Dermira, Inc.
DERM
$94.7M 3.32%
3,506,649
– –
AKAO
8
DELISTED
Achaogen Inc
AKAO
$83.2M 2.91%
5,215,128
– –
ARDX icon
9
Ardelyx
ARDX
$1.23B
$78.9M 2.76%
14,083,582
– –
SYBX
10
DELISTED
Synlogic
SYBX
$72.6M 2.54%
254,627
+226,295
+799% +$46.3M
AVEO
11
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$59.7M 2.09%
1,636,269
– –
CRSP icon
12
CRISPR Therapeutics
CRSP
$4.64B
$57.6M 2.02%
3,220,728
– –
CRCM
13
DELISTED
CARE.COM, INC.
CRCM
$51.8M 1.81%
3,260,989
– –
RARX
14
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$51M 1.79%
3,493,636
– –
IMMU
15
DELISTED
Immunomedics Inc
IMMU
$38.8M 1.36%
+2,772,643
New +$27.6M
CASC
16
DELISTED
Cascadian Therapeutics, Inc.
CASC
$37.1M 1.3%
9,064,575
– –
CMTA
17
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$36.2M 1.27%
+2,141,697
New +$35M
AUPH icon
18
Aurinia Pharmaceuticals
AUPH
$1.92B
$30.1M 1.06%
4,808,483
– –
LXRX icon
19
Lexicon Pharmaceuticals
LXRX
$1.03B
$29.3M 1.03%
2,382,286
– –
SBBP
20
DELISTED
Strongbridge Biopharma plc.
SBBP
$28.6M 1%
4,141,308
– –
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
$27.2M 0.95%
3,336,563
– –
VRNA
22
DELISTED
Verona Pharma
VRNA
$18.7M 0.66%
1,219,674
+553,008
+83% +$7.3M
TNTR
23
DELISTED
Tintri, Inc. Common Stock
TNTR
$16.5M 0.58%
5,253,358
– –
SCMP
24
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$14.8M 0.52%
1,258,507
– –
RGLS
25
DELISTED
Regulus Therapeutics
RGLS
$13.7M 0.48%
+91,583
New +$11.5M
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q3 2017 Portfolio in Review

As of Q3 2017, NEA Management Company held 49 positions worth $2.86B, up 3.9% from $2.75B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

NEA Management Company's Q3 2017 filing shows 5 new, 3 increased and 5 closed positions. Its largest new stake was Clementia Pharmaceuticals Inc.: 2,141,697 shares worth $36.2M. The largest sale was Groupon, an estimated $38.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Consumer Discretionary and Technology.

  • NEA Management Company's largest Q3 2017 buy was Clementia Pharmaceuticals Inc.: 2,141,697 shares worth $36.2M.
  • NEA Management Company added most to Synlogic in Q3 2017, an estimated $46.3M increase.
  • NEA Management Company fully exited Groupon in Q3 2017, selling an estimated $38.5M.
  • NEA Management Company's ten largest holdings make up 79% of its $2.86B portfolio in Q3 2017.
  • NEA Management Company opened 5 new positions and closed 5 in Q3 2017.
  • NEA Management Company's portfolio value rose 3.9% quarter-over-quarter to $2.86B.

Based on NEA Management Company's 13F filing for Q3 2017, filed 3 Nov 2017.